JMP Securities Reaffirms “Market Perform” Rating for Inhibrx (NASDAQ:INBX)

JMP Securities reiterated their market perform rating on shares of Inhibrx (NASDAQ:INBX) in a report released on Wednesday morning,Benzinga reports.

Inhibrx Stock Up 0.5 %

Inhibrx stock opened at $13.15 on Wednesday. The business’s 50-day moving average price is $14.62 and its 200 day moving average price is $14.65. Inhibrx has a 52 week low of $10.80 and a 52 week high of $18.95.

Insider Activity

In other news, Director Jon Faiz Kayyem purchased 69,686 shares of the stock in a transaction that occurred on Tuesday, November 19th. The shares were purchased at an average cost of $14.23 per share, with a total value of $991,631.78. Following the completion of the acquisition, the director now owns 51,093 shares of the company’s stock, valued at approximately $727,053.39. This represents a -374.80 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 22.20% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of INBX. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Inhibrx during the 4th quarter valued at about $47,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management purchased a new position in Inhibrx during the fourth quarter worth approximately $348,000. Finally, Exchange Traded Concepts LLC acquired a new stake in Inhibrx in the fourth quarter valued at approximately $148,000. Institutional investors and hedge funds own 82.46% of the company’s stock.

About Inhibrx

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.